#ClinicalTrial EAQ221CD/CONCURxP strives to improve medication adherence in #metastatic #BreastCancer patients. If you have a new prescription for a CDK4/6 inhibitor you may be eligible. Learn more here: https://bit.ly/EAQ221CD
New Video: Study chair @Raquib_Hannan of @UTSW_RadOnc and advocate Glenn Sykes discuss this trial that is testing a new treatment approach for patients with #KidneyCancer that has spread to 5 or fewer other locations in the body. cc: @SuzanneColeMD
Do you have chronic myelogenous #leukemia (#CML)? If so, you may be able to participate in this study of a potential new treatment. Learn more: https://bit.ly/ea9171-study #leusm #BloodCancer cc: @Dr_AmerZeidan
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
Active Clinical Trials
Participating Institutions
International Sites
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).